Alpha-1 Antitrypsin Deficiency (AATD) Market Size, Share, and Growth Forecast, 2026 – 2033

The global alpha?1 antitrypsin deficiency (AATD) market size is likely to be valued at US$?4.2?billion in 2026, and is projected to reach US$?9.7?billion by 2033, growing at a CAGR of 12.7?% during the forecast period 2026?–?2033. Market expansion is primarily fueled by the rising prevalence of genetic respiratory disorders, such as chronic obstructive pulmonary disease (COPD) and emphysema, which are frequently associated with AATD.

Advances in targeted therapies, including augmentation therapy, gene therapy, and RNA-based interventions, are improving treatment efficacy and patient outcomes. Concurrently, the adoption of genetic testing, biomarker assays, and pulmonary function monitoring is increasing early detection rates, enabling timely clinical intervention. Supportive regulatory frameworks, such as orphan drug designations, coupled with investments in healthcare infrastructure and expansion of specialty clinics, are enhancing patient access and long-term market growth prospects.